Selank vs NA-Selank-Amidate
Comparing original Selank with its N-acetyl amidated derivative NA-Selank-Amidate for stability and bioavailability.
Last updated: February 1, 2026
Selank
N-Acetyl Selank Amidate
Overview
Selank and NA-Selank-Amidate share the same core structure, but NA-Selank-Amidate has N-acetylation and C-terminal amidation modifications. These changes aim to improve stability and bioavailability. Selank is approved in Russia as an anxiolytic; NA-Selank-Amidate has no approval anywhere.
Key Facts
| Aspect | Selank | NA-Selank-Amidate |
|---|---|---|
| Base Structure | Tuftsin + Pro-Gly-Pro | Same core |
| N-terminus | Free (Thr) | Acetylated |
| C-terminus | Free carboxyl | Amidated |
| Amino Acids | 7 | 7 |
| Approval Status | Russia | Nowhere |
Structural Modifications
N-Acetylation
| Aspect | Information |
|---|---|
| Modification | Acetyl group on N-terminal threonine |
| Purpose | Protect from aminopeptidase degradation |
| Expected Effect | Improved metabolic stability |
| Trade-off | May affect receptor binding |
C-Terminal Amidation
| Aspect | Information |
|---|---|
| Modification | Convert -COOH to -CONH2 |
| Purpose | Protect from carboxypeptidase degradation |
| Expected Effect | Improved metabolic stability |
| Trade-off | May affect activity |
Rationale for Modifications
Peptide degradation occurs via:
- Aminopeptidases - cleave from N-terminus
- Carboxypeptidases - cleave from C-terminus
- Other proteases - internal cleavage
Modifications address #1 and #2, potentially extending half-life.
Evidence Comparison
| Aspect | Selank | NA-Selank-Amidate |
|---|---|---|
| Human Trials | Some (Russia) | None |
| Regulatory Review | Russian approval | Never reviewed |
| Published Research | Multiple studies | Virtually none |
| Safety Data | Some (Russia) | None |
The Evidence Gap
Selank:
- Approved anxiolytic in Russia
- Some clinical experience
- Published mechanism studies
- Known side effect profile
NA-Selank-Amidate:
- No clinical trials
- No published comparative studies
- Assumes modifications preserve activity
- Unknown if modifications affect receptor binding
Proposed vs Proven Effects
Selank (Russian Data)
| Effect | Evidence |
|---|---|
| Anxiolytic | Russian clinical trials |
| Nootropic | Claimed, limited data |
| Immunomodulation | Preclinical |
| GABA modulation | Mechanism studies |
NA-Selank-Amidate (No Data)
| Claim | Status |
|---|---|
| Same effects as Selank | Assumed |
| Improved stability | Theoretical |
| Better bioavailability | Not measured |
| Enhanced efficacy | No evidence |
Administration
| Aspect | Selank | NA-Selank-Amidate |
|---|---|---|
| Route | Intranasal | Intranasal (assumed) |
| Duration | Per prescription | Unknown |
Safety Considerations
| Factor | Selank | NA-Selank-Amidate |
|---|---|---|
| Human Safety | Russian post-market | None |
| Side Effects Known | Yes | No |
| Drug Interactions | Some data | None |
| Long-term Use | Some data | None |
Uncertainty with Modified Form
- Modifications may create different metabolites
- Receptor binding affinity may change
- New side effects possible
- No safety testing conducted
Regulatory Status
| Aspect | Selank | NA-Selank-Amidate |
|---|---|---|
| Russia | Approved (anxiolytic) | Not approved |
| US/EU | Not approved | Not approved |
| Quality Sources | Russian pharmacies | Research chemical |
| Pharmaceutical Grade | Yes (Russia) | No |
Quality and Access
| Factor | Selank | NA-Selank-Amidate |
|---|---|---|
| Pharmaceutical | Available (Russia) | Not available |
| Research Chemical | Available | Available |
| Quality Control | Variable | None |
| Purity | Verifiable (some) | Unknown |
Key Differences
| Factor | Selank | NA-Selank-Amidate |
|---|---|---|
| Modifications | None | N-acetyl + C-amide |
| Evidence Level | Moderate (Russian) | None |
| Regulatory | Russia approved | None |
| Stability | Standard | Theoretically improved |
| Clinical Experience | Some | None |
The Modification Assumption
Many assume NA-Selank-Amidate is “better” because:
- Modifications are common peptide chemistry
- Should improve stability
- Should improve bioavailability
However:
- No comparative studies exist
- Modifications may alter binding affinity
- Optimal dosing unknown
- Safety not established
Summary
- Selank has Russian approval and some clinical background for anxiety
- NA-Selank-Amidate has modifications for theoretical stability but no evidence
- Modifications are chemically rational but unverified
- No studies compare the two forms
- Neither is FDA/EMA approved
- Selank has some pharmaceutical availability; NA-Selank-Amidate does not
- Research chemical quality is uncertain for both
This comparison is for educational purposes only. Neither compound is approved by the FDA or EMA. NA-Selank-Amidate has no clinical data. Products sold as research chemicals have uncertain quality and safety.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.